Related Experiment Video
Updated: Jun 2, 2026

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing
T C Felizardo1, J C M Wang, R A J McGray
1Campbell Family Cancer Research Institute and Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Abstract:
Recent investigations have demonstrated that adenoviral and lentiviral vectors encoding HER-2 can be utilized in cancer immunotherapy. However, it is not known whether both viral systems elicit a similar immune response. Here, we compare the immune response in mice induced by dendritic cells (DCs) infected with either recombinant adenovirus or lentivirus encoding rat HER-2 (rHER-2). Both vaccine types yielded similar control of tumor growth, but we found clear differences in their immune responses 10 days after DC immunization. Adenovirus rHER-2-transduced DCs elicited locally and systemically high frequencies of CD4+ and CD8+ T cells, while lentivirus rHER-2-transduced DCs predominantly led to CD4+ T-cell infiltration at the tumor site. Splenocytes from mice immunized with lentivirus rHER-2-transduced DCs secreted higher levels of interferon (IFN)-γ, mainly by CD4+ T cells, following stimulation by RM-1-mHER-2 tumors. In contrast, the adenovirus vaccinated group exhibited CD4+ and CD8+ T cells that both contributed to IFN-γ production. Besides an established cellular immune response, the rHER-2/DC vaccine elicited a significant humoral response that was highest in the adenovirus group. DC subsets and regulatory T cells in the spleen were also differentially modulated in the two vaccine systems. Finally, adoptive transfer of splenocytes from both groups of immunized mice strongly inhibited in vivo tumor growth. Our results suggest that not only the target antigen but also the virus system may determine the nature and magnitude of antitumor immunity by DC vaccination.
Insights
This study compared adenoviral and lentiviral HER-2 cancer vaccines in mice. Both controlled tumor growth, but viral vectors induced distinct immune responses, influencing T-cell types and cytokine production for antitumor immunity.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Adenoviral and lentiviral vectors encoding HER-2 are used in cancer immunotherapy.
- The comparative immune response of these viral systems is not well understood.
Purpose of the Study:
- To compare the immune responses induced by dendritic cells (DCs) infected with either recombinant adenovirus or lentivirus encoding rat HER-2 (rHER-2).
- To evaluate the impact of viral vector systems on antitumor immunity.
Main Methods:
- Mice were immunized with dendritic cells (DCs) infected with adenovirus or lentivirus encoding rat HER-2 (rHER-2).
- Immune responses, including T-cell infiltration, cytokine production (IFN-γ), and humoral response, were analyzed.
- Tumor growth inhibition was assessed via adoptive transfer of splenocytes.
Main Results:
- Both vaccine types controlled tumor growth similarly.
- Adenovirus-transduced DCs induced higher frequencies of CD4+ and CD8+ T cells, while lentivirus-transduced DCs primarily led to CD4+ T-cell infiltration.
- Lentivirus vaccination resulted in higher IFN-γ secretion mainly by CD4+ T cells, whereas adenovirus vaccination showed IFN-γ production from both CD4+ and CD8+ T cells.
- Adenovirus vaccination elicited a stronger humoral response.
Conclusions:
- The viral vector system, in addition to the target antigen, influences the nature and magnitude of antitumor immunity generated by DC vaccination.
- Both adenoviral and lentiviral HER-2/DC vaccines promote significant antitumor immunity, but through distinct immune response profiles.
More Related Videos
07:02Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
Published on: September 14, 2010
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014